Key Points {#FPar1}
==========

No statistically significant differences in blood aggregation and pharmacokinetics of clopidogrel and its metabolites were found between *CYP3A4\*1G* carriers and non-carriers.

Introduction {#Sec1}
============

Clopidogrel (CLP) is a second-generation thienopyridine antiplatelet drug \[[@CR1]\] Double antiplatelet therapy, which combines 75 mg of CLP and 75-325 mg of acetylsalicylic acid (aspirin) administered daily, is considered "a gold standard" in prevention of stent thrombosis after percutaneous coronary intervention \[[@CR2]\]. However, 5--50 % of patients treated with CLP respond poorly to the drug \[[@CR3], [@CR4]\]. This phenomenon called "CLP resistance" is a main reason of the antiplatelet therapy failure, which may lead to ischaemic events and patient's death. Many genetic and non-genetic factors are considered to be significant contributors to CLP resistance \[[@CR5]\]. Among non-genetic factors are diabetes mellitus, impaired glucose tolerance, chronic kidney disease, ongoing inflammatory states, obesity and smoking. However, most widely discussed potential causes of CLP resistance are genetic polymorphisms of enzymes contributing to metabolic activation of CLP. CLP is a prodrug that is converted to the active, thiol metabolite in a two-step reaction catalyzed by CYP450 isoenzymes (CYP2C19, CYP3A4, CYP2B6, CYP1A2, CYP2C9) \[[@CR6]\]. Thiol metabolite is detected in plasma as two diastereoisomers, H3 and H4, but only H4 exhibits antiaggregation properties \[[@CR7]\]. Approximately 15 % of absorbed drug undergoes this metabolic pathway, while 85 % is hydrolyzed into an inactive carboxylic acid derivative (CLPM). Among CYP450 that take part in CLP bioactivation, CYP2C19 is of greatest importance. Many studies and meta-analyses have shown that carriers of CYP2C19 loss-of-function alleles are more susceptible to CLP resistance and high-on-treatment platelet reactivity and, therefore, to the occurrence of adverse cardiovascular events \[[@CR8], [@CR9]\]. According to Kazui et al. \[[@CR6]\] CYP3A4 is responsible for transformation of 39.8 % of an intermediate product, 2-oxo-CLP, into the thiol entities. Therefore, altered activity of CYP3A4 resulting from genetic polymorphisms might have an influence on the yield of active metabolite formation and subsequently on the antiplatelet effect of the drug. Moreover, patients treated with CLP are often simultaneously treated with other drugs, such as statins or calcium channel blockers (CCB), that might be substrates of CYP3A4 and enhance or inhibit the function of this enzyme. Such interactions could have an influence on concentrations of H3 and H4 metabolites and the effectiveness on CLP treatment. Therefore, coadministration of those drugs cannot be neglected. In present study, we intended to evaluate influence of *CYP3A4\*1G (IVS10*+*12G*\>*A, rs2242480)* on CLP pharmacokinetics and pharmacodynamics. *CYP3A4\*1G* is a single nucleotide polymorphism present in intron 10 of *CYP3A4* with a possible enhancer and promoter activity \[[@CR10]\]. Several studies have shown that the presence of *CYP3A4\*1G* can be associated with altered pharmacokinetics of several drugs metabolized by CYP3A, such as fentanyl \[[@CR11]\], atorvastatin \[[@CR12]\] and tacrolimus \[[@CR13]\]. So far only the influence of *CYP3A4\*1G* on pharmacodynamic effect of CLP was evaluated \[[@CR14]--[@CR16]\]. To our knowledge this is the first study that investigates influence of *CYP3A4\*1G* on pharmacokinetics of CLP in patients, with an emphasis on the active metabolite of CLP.

Materials and Methods {#Sec2}
=====================

Study Group {#Sec3}
-----------

A total number of 82 patients were recruited between 2011 and 2013 for participation in this observational study. All patients were of Caucasian origin and were scheduled for percutaneous coronary intervention (PCI) or coronarography. Patients were treated with 75 mg CLP daily for 7 days prior to the procedure to ensure achieving maximum level of platelet inhibition \[[@CR17]\]. CLP was administered under fasting conditions. Exclusion criteria were acute myocardial infarction, malignancies, oral anticoagulation therapy with a coumarin derivative, treatment with a glycoprotein IIb/IIIa antagonist or other antiplatelet drugs except for aspirin, platelet count \<100,000/μL, current liver dysfunction or impaired renal function (serum creatinine concentration 2 mg/dL).

Sample Collection {#Sec4}
-----------------

The sampling was performed on the seventh day of treatment with 75 mg of CLP. In 44 patients a pharmacokinetic profile of CLP and its metabolites was determined from samples collected 0.5, 1, 2, 3, 4, 6, 12 and 24 h after CLP administration. In 38 patients only 2 samples (0.5 and 2 h after CLP administration) were collected. 7.5 mL of full blood was transferred into collection systems containing ethylenediaminetetraacetic potassium salt (EDTA-K) (Sarstedt AG & Co., Germany) and immediately spiked with 37.5 μL of a 500 mM acetonitrile solution of 2-bromo-3-methoxyacetophenone (MPB). The addition of MPB is required for stabilization of reactive thiol H3 and H4 metabolites, as described by Takahashi et al. \[[@CR18]\]. Approximately 1 mL of full blood was transferred into a clean polypropylene tube and stored at −25 °C until DNA isolation. Remaining aliquots of full blood were centrifuged for 10 min at 1620×*g* and separated plasma was stored at −25 °C until further analysis.

Genotyping {#Sec5}
----------

Genomic DNA was isolated from 100 μL of blood using commercially available kit according to manufacturer's instruction (Blood Mini, A&A Biotechnology, Poland). *CYP3A4\*1G* was identified by a PCR-restriction fragment length polymorphism method (RFLP). Reference sequence was obtained from Gene Bank (<http://www.ncbi.nih.gov>). The amplification cycles were performed in a T100 thermocycler (BIORAD, Singapore). Following settings were used: initial denaturation at 94 °C for 5 min, 37 cycles with denaturation at 94 °C for 30 s, annealing at 55 °C for 45 s and elongation at 72 °C at 30 s with subsequent final elongation at 72 °C for 7 min. Primers were designed in the Primer3Plus software \[[@CR19]\] and sequences were as follows: F: 5′-CGTGGCCCAATCAATTATCT-3′, R: 5′-TTCTCCTGGGAAGTGGTGAG-3′. The reaction was performed in a volume of 25 μL with 1 μL of isolated DNA, 0.5 μM of each primer, 0.2 mM of each dNTP and 1 unit of DreamTaq polymerase in 1× PCR buffer (Thermo Scientific, Great Britain). MgCl~2~ was added to the reaction mix up to the final concentration of 2.5 mM. To detect the studied CYP3A4\*1G polymorphism, the PCR product (220 bp) was digested with RsaI endonuclease (Roche Diagnostics, Germany). 15 μL of the product was incubated in 37 °C for 1 h in a mixture consisting of 1 U of the RsaI enzyme and 2.5 μL of 10× concentrated restriction buffer L, provided by the manufacturer. Water was added to make up a final volume of 25 μL. Digestion products were separated in a 3 % agarose gel. Two fragments (155 and 65 bp) were observed in wt/wt homozygotes, one fragment (220 bp) in *\*1G*/*\*1G* homozygotes and 3 fragments in heterozygotes. RFLP analysis results were confirmed by sequencing the PCR product from 10 randomly selected samples, on a 3130xl Genetic Analyzer (Applied Biosystems HITACHI, USA). In present study, CYP2C19 phenotype was also included as a potential covariate influencing CLP response in a multivariate analysis. A detailed study of the effect of *CYP2C19* on CLP pharmacokinetics and methods for CYP2C19 phenotype evaluation were described previously by Karaźniewicz-Łada et al. \[[@CR20]\]. Briefly, CYP2C19 phenotype was determined according to the presence of *\*1*, *\*2* and *\*17* alleles in CYP219 gene. *CYP2C19\*2* was determined by a PCR--RFLP method, as described by Giusti et al. \[[@CR15]\] while an allele-specific PCR was performed to analyze *CYP2C19\*17* as described by Sim et al. \[[@CR21]\]. Patients with *\*1/\*17* and *\*17/\*17* diplotypes were classified as ultrarapid metabolizers (UM), *\*1/\*1*---extensive metabolizers (EM) and *\*1/\*2* and *\*2/\*17*---intermediate metabolizers (IM).

Pharmacokinetic and Pharmacodynamic Analysis {#Sec6}
--------------------------------------------

Concentrations of CLP and its metabolites were determined by a validated HPLC--MS/MS method, described by Karaźniewicz-Łada et al. \[[@CR22]\]. The analysis was performed on an Agilent 1200 chromatograph coupled with 6410B Triple Quad tandem mass spectrometer (Agilent Technologies, USA). CLP, H3 and H4 derivatives, CLPM and internal standard (piroxicam) were separated in a Zorbax Plus C18 column (Agilent Technologies, USA) at 40 °C. Mobile phase consisted of water and HPLC gradient-grade acetonitrile (Merck, Germany) acidified with 0.1 % of formic acid. Specific transitions for the analytes were monitored in a multiple reaction monitoring (MRM) mode. Sample preparation was as follows: 250 µL of plasma was spiked with 25  µL of an internal standard solution (1000 ng/mL piroxicam). Proteins were precipitated by adding 475 µL of acetonitrile. Subsequently, samples were centrifuged (22,570×*g*) and supernatant was filtrated through 0.45 µm Mini UniPrep filters with regenerated cellulose (Agilent Technologies, UK). The filtrate was evaporated in vacuum under 40 °C. Prior to injection the dry residue was reconstituted in 200 µL of mixture consisting of acetonitrile and water (50:50, v/v) with 0.1 % formic acid. The concentrations of analytes were calculated from calibration curves, which were analyzed prior to each analytical run according to European Medicines Agency guidelines for Bioanalytical Method Validation \[[@CR23]\]. The quantification ranges were as follows: for CLP: 0.25--5 ng/mL; for bromomethoxy derivatives of H3 and H4: 0.25--50 ng/mL; for CLPM: 50--10,000 ng/mL. Pharmacokinetic parameters of the analytes were calculated by a non-compartmental method using WinNonlin 6.2 (Pharsight, USA). The area under the concentration--time curve (AUC~0--t~) was estimated by trapezoidal rule. Elimination half-life (*t* ~1/2~) was estimated from ln2/*k*, where *k* is the elimination rate constant calculated from terminal segment of log plasma concentration--time plot. Maximum concentration (*C* ~max~) and time to reach *C* ~max~ (*t* ~max~) were established directly from measured plasma concentrations.

Pharmacodynamic response was estimated by an impedance method (Multiplate analyzer; Roche Diagnostics). Samples for the assay were collected into hirudin-coated S-Monovette systems (Sarstedt AG&Co., Germany) 2--3 h after CLP administration. The ADP-induced platelet aggregation test was performed in accordance with manufacturer's instruction. Platelet aggregation was quantified as the area under the curve (AUC~aggr~) of arbitrary units vs. time (AU·min).

Statistical Analysis {#Sec7}
--------------------

Shapiro--Wilk test was performed to establish normality of the data. The differences between normally distributed variables in two groups were determined with Student's *t* test, otherwise Mann--Whitney *U* test was applied. Multivariate analysis was performed to estimate influence of *CYP3A4\*1G* and other covariates on pharmacokinetic parameters of CLP and its metabolites and pharmacodynamic response. For calculating the Hardy--Weinberg equilibrium, an online calculation tool was used \[[@CR24]\]. Otherwise, statistical calculations were performed in Statistica 10 software (StatSoft, USA). A *p* ≤ 0.05 was considered statistically significant.

Results {#Sec8}
=======

Study Group Characteristics {#Sec9}
---------------------------

Data collected from all 82 patients were included in the study. Majority of patients were suffering from at least one co-morbidity, such as diabetes mellitus, hypertension or dyslipidemia. Beside CLP and aspirin most frequently coadministered drugs were statins, beta-adrenergic blocking agents (BB) and proton pump inhibitors (PPI). Detailed patients' characteristics are described in Table [1](#Tab1){ref-type="table"}.Table 1Baseline patients' characteristicsCharacteristic*CYP3A4\*1G*Total number of patients (*n* = 82)*wt/wt* (*n* = 69)*wt/\*1G* (*n* = 13)Age (years)62 ± 9.563.5 ± 9.368.4 ± 9.7BMI (kg/m^2^)28.69 ± 4.8329.0 ± 4.927.0 ± 3.7Male/female55/27 (67.1 %/32.9 %)44/25 (63.8 %/36.2 %)11/2 (84.6 %15.4 %)Diabetes mellitus/impaired glucose tolerance30 (36.6 %)25 (36.2 %)5 (38.5 %)Hypertension71 (86.6 %)59 (85.5 %)12 (92.3 %)Hyperlipidaemia24 (29.3 %)19 (27.5 %)5 (28.5 %)Hypercholesterolaemia14 (17.1 %)13 (18.8 %)1 (7.7 %)Co-medications Statins  Atorvastatin53 (64.6 %)44 (63.8 %)9 (69.2 %)  Simvastatin10 (12.2 %)10 (14.5 %)0  Rosuvastatin14 (17.1 %)11 (15.9 %)3 (23.1 %)PPI44 (53.7 %)37 (53.6 %)7 (53.8 %)CCB23 (28.0 %)21 (30.4 %)2 (15.4 %)ARB11 (13.4 %)11 (15.9 %)0ACE-I61 (74.4 %)53 (76.8 %)8 (61.5 %)BB74 (90.2 %)63 (91.3 %)11 (84.6 %)Allele frequencies*wt* = 0.921*\*1G* = 0.179Age and BMI are presented as mean ± standard deviation*PPI* proton pump inhibitor, *CCB* calcium channel blocker, *ARB* angiotensin receptor blocker, *ACE-I* angiotensin-converting enzyme inhibitor, *BB* beta blocker, *wt* wild-type allele

Genotyping {#Sec10}
----------

Genotype distribution and allele frequencies of the *CYP3A4\*1G* polymorphism are presented in Table [1](#Tab1){ref-type="table"}. Studied SNP was in Hardy--Weinberg equilibrium. 84.1 % of patients were *wt/wt* homozygotes, while 15.9 % were heterozygotes. We did not observe any *\*1G/\*1G* homozygotes in studied population.

Pharmacokinetics and pharmacodynamics {#Sec11}
-------------------------------------

Figure [1](#Fig1){ref-type="fig"} illustrates mean pharmacokinetic profiles of CLP and each metabolite---CLPM, H3 and H4 in patients with *wt/wt* and *wt/\*1G* genotypes. Concentrations of the main metabolite (CLPM) were quantifiable up to 24 h after CLP administration. However, the parent compound and thiol metabolites are rapidly eliminated and their concentrations were below level of quantitation in majority of samples collected 4 h after drug administration \[[@CR25]\]. Pharmacokinetic profiles for studied analytes were similar between homozygotes and heterozygotes. There were no statistically significant differences in mean concentrations at measurement times for CLP and its metabolites (p values ranging from 0.293 to 0.922).Fig. 1Pharmacokinetic profiles of clopidogrel (CLP) and its metabolites. Concentrations are presented as medians with standard deviation as *whiskers*

The comparison of calculated pharmacokinetic parameters of CLP and its metabolites is presented in Table [2](#Tab2){ref-type="table"}. Due to very low concentrations of a parent drug and thiol metabolites, we were not able to detect the analytes in all collected samples. Therefore, patient numbers presented in Table [2](#Tab2){ref-type="table"} vary between groups. Performed statistical analysis showed, that the values of pharmacokinetic parameters were not significantly different.Table 2Comparison of pharmacokinetic parameters of clopidogrel (CLP) and its metabolites according to CYP3A4\*1G status. *CYP* cytochrome P450Pharmacokinetic parameter*wt/wtwt/\*1Gp***CLP*n*** **=** **32*n*** **=** **6** AUC~0--t~ (ng·h/mL)3.88 (2.23--7.80)4.42 (2.51--6.86)0.979 *C* ~max~ (ng/mL)1.37 (0.61--2.42)1.60 (1.03--2.09)0.761 *T* ~max~ (h)1.00 (0.50--2.00)1.00 (0.50--2.00)0.699 *t* ~1/2~ (h)1.15 (0.72--2.33)1.20 (0.76--1.96)0.816 Cl (L/h)15,607 (8657--22,846)14,365 (8694--26,772)0.979 *V* ~d~ (L)34,652 (13,840--69,963)28,763 (21,447--35,866)0.897**CLPM*n*** **=** **35*n*** **=** **9** AUC~0--t~ (ng·h/mL)10,137 (6998--12,135)7712 (7012--8118)0.282 *C* ~max~ (ng/mL)1952 (1449--2802)2560 (2116--3512)0.171 *T* ~max~ (h)1.00 (0.75--2.00)1.00 (0.50--2.00)0.692 *t* ~1/2~ (h)7.19 (5.13--9.31)6.55 (3.42--8.56)0.602**H3*n*** **=** **23*n*** **=** **6** AUC~0--t~ (ng·h/mL)5.69 (3.27--7.69)5.70 (1.68--10.14)0.417 *C* ~max~ (ng/mL)3.41 (1.97--5.47)2.07 (1.45--15.55)0.686 *T* ~max~ (h)1.00 (0.50--1.00)1.00 (0.50--2.00)0.752 *t* ~1/2~ (h)0.52 (0.32--0.87)0.53 (0.37--0.66)0.976**H4*n*** **=** **23*n*** **=** **6** AUC~0--t~ (ng·h/mL)7.59 (4.73--18.83)6.52 (2.55--10.01)0.484 *C* ~max~ (ng/mL)5.15 (3.10--10.07)4.62 (2.15--10.18)0.979 *T* ~max~ (h)1.00 (0.50--1.00)1.00 (1.00--2.00)0.286 *t* ~1/2~ (h)0.65 (0.39--0.99)0.42 (0.32--1.18)0.324Data are presented as medians with interquartile range*AUC* ~*0--t*~ area under time--concentration curve, *C* ~*max*~ maximum concentration, *T* ~*max*~ time to reach maximum concentration, *k* elimination constant, *t* ~*1/2*~ elimination half-life

In Fig. [2](#Fig2){ref-type="fig"} is presented the pharmacodynamic effect of CLP depending on CYP3A4 genotype. Almost all studied patients were classified as responders to the CLP. Only one patient exhibited AUC~agr~ above 486 AU\*min which is considered as a threshold value for CLP resistance \[[@CR26]\]. Median AUC~agr~ for wt/wt genotype was lower than AUC~agr~ for heterozygotes. However, the observed difference was not statistically significant (*p* = 0.484).Fig. 2Platelet aggregation (AUC~agr~) according to *CYP3A4\*1G* genotype. Data are presented as medians with *boxed* interquartile range. *Whiskers* represent minimum-maximum range

Multivariate Analysis {#Sec12}
---------------------

Multivariate analysis was performed to estimate, whether *CYP3A4\*1G* allele might be an important covariate of CLP active metabolite pharmacokinetics and pharmacodynamics. We have investigated the influence of *CYP3A4\*1G* on C~max~ and AUC~0--t~ of H3 and H4, and AUC~agr~. Following characteristics were examined as potential covariates: gender, age, BMI, diabetes mellitus, co-medications: statins, PPI, CCB, and CYP2C19 phenotype. Due to the fact that majority of patients were treated with statins, which vary widely in pharmacokinetic properties, we have focused on comparison of the type of statin (atorvastatin, simvastatin, rosuvastatin). To ensure normal distribution of the variables, values of pharmacokinetic parameters were logarithmically transformed. We have found that *CYP3A4\*1G* remained a non-significant factor when it was included in a multivariate analysis with the covariates mentioned above. Noteworthy, neither patients' characteristics nor coadministered drugs were significantly influencing pharmacokinetics of CLP and its metabolites. Only CYP2C19 phenotype had an impact on H4 *C* ~max~ and AUC~0--t~, although a model including both *CYP3A4\*1G* and CYP2C19 phenotype was not statistically significant (Fig. [3](#Fig3){ref-type="fig"}). Mean *C* ~max~ and AUC~0--t~ values of H4 active metabolite were similar in GG and GA carriers; however, there was a visible difference in the analyzed parameters between CYP2C19 phenotypes: UM, EM and IM. Detailed results of multivariate analysis are presented as supplementary material (Online Resource 1, 2 and 3).Fig. 3Influence of *CYP3A4\*1G* and CYP2C19 phenotype on *C* ~max~ (**a**) and AUC~0--t~ (**b**) of H4 metabolite. Data are presented as means with 95 % confidence intervals as whiskers. Presented values of *p* refer to the model. *UM* CYP2C19 ultrarapid metabolizer, *EM* CYP2C19 extensive metabolizer, *IM* CYP2C19 intermediate metabolizer, AUC~0--t~ area under the concentration time curve from time zero to time t, *C* ~*max*~ maximum plasma concentration, *CYP* cytochrome P450

Discussion {#Sec13}
==========

Effective antiplatelet treatment is particularly important in patients with a high risk of cardiovascular events. CLP is a widely used drug in prevention of thrombosis. However, occurrence of CLP resistance which has both non-genetic and genetic background diminishes effectiveness of the therapy. Polymorphisms of *CYP2C19* are most widely studied among genetic factors. Presence of loss-of-function alleles, most notably *\*2* and *\*3*, is associated with higher platelet reactivity and, therefore, higher risk of antiplatelet treatment failure \[[@CR27], [@CR28]\]. Influence of *CYP3A4\*1G* on CLP pharmacokinetics and pharmacodynamics is unclear. Some authors notice, that the presence of *CYP3A4\*1G* might be connected with lower activity of the enzyme \[[@CR29], [@CR30]\]. Yuan et al. \[[@CR29]\] have recently found that *CYP3A4\*1G* is associated with lower expression of CYP3A4 defined as mRNA concentration. The authors have also noticed a significant positive correlation between *CYP3A4* mRNA and in vitro metabolic rate of fentanyl, which is predominantly metabolized by CYP3A4. Since CYP3A4 is one of the enzymes participating in bioactivation of CLP, lower concentrations of H3 and H4, as well as higher platelet reactivity might be observed in carriers of *\*1G* allele. In our study, *\*1G* allele frequency was similar in comparison to other studies that included European populations \[[@CR14], [@CR15]\]. We did not observe statistically significant difference in platelet reactivity. However, median AUC~agr~ was higher in heterozygotes than in wild-type homozygotes. This finding is consistent with the results obtained by Fontana et al. \[[@CR31]\], who did not find any association between *CYP3A4\*1G* and platelet aggregation following administration of the same dose of CLP. However, it is contrasting with a study by Angiollilo et al. \[[@CR14]\]. It showed that presence of polymorphic allele variant was associated with lower ADP-induced platelet aggregation. Above-mentioned studies focused only on the influence of CYP3A4 polymorphism on pharmacodynamic effect of the drug and did not include plasma concentrations of CLP and its metabolites. In the present study pharmacokinetic aspect of drug effectiveness was also considered. The results showed that in CYP3A4\*1G carriers concentrations of CLP and its metabolites and values of calculated pharmacokinetic parameters were not significantly different as compared to wt/wt homozygotes (Fig. [1](#Fig1){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}).

CYP3A4 is responsible for transformation of almost 40 % of 2-oxo-CLP to the active thiol metabolite \[[@CR6]\]. We investigated if *\*1G* allele might influence CLP pharmacokinetics and pharmacodynamics in the presence of known CYP3A4 substrates (CCB, omeprazole and other PPI, atorvastatin and simvastatin). In an article by Park et al. \[[@CR32]\], carriers of *\*1G* allele were more vulnerable to occurrence of high-on-treatment platelet reactivity while being treated with CCB. In the present study, we did not observe a relationship between concomitant use of CCB, presence of *\*1G* and antiplatelet effect of CLP and active metabolite pharmacokinetics. An impact of coadministration of PPI, most noteworthy omeprazole, on the efficacy of CLP therapy is most widely discussed. It was noticed that *C* ~max~ and AUC~0--t~ of CLP active metabolite were lower and the platelet aggregation was higher while omeprazole or esomeprazole were administered \[[@CR33], [@CR34]\]. However, in our study after controlling for this covariate the difference in H3 and H4 pharmacokinetic parameters in *\*1G* carriers remained not significantly different. Statins that are mostly metabolized by CYP3A4 might also influence lower rate of formation of H3 and H4. In present study, statistical analysis did not show a significant influence of statins and *CYP3A4\*1G* on pharmacokinetics of CLP active metabolite in the study group.

The factors of largest influence on CLP pharmacokinetics and pharmacodynamics are CYP2C19 loss-of-function alleles. Park et al. \[[@CR16]\] noticed that in CYP2C19 poor metabolizers *CYP3A4\*1G* was related with lower value of P2Y~12~ reaction units. Authors suggest that *\*1G* polymorphism might have an impact on CLP efficacy only in patients with severe CYP2C19 dysfunction. We have found that after including patients' CYP2C19 phenotype into the model there was no statistically significant difference in AUC~agr~ and pharmacokinetic parameters of H3 and H4. However, CYP2C19 phenotype remained significant predictor of H4 *C* ~max~ and AUC~0--t~. It is consistent with article presented by Giusti et al. \[[@CR15]\]. The authors report no influence of *CYP3A4\*1G* on ADP-induced aggregation, while *CYP2C19\*2*, most common CYP2C19 loss-of-function allele, was associated with response variability. In conclusion, *CYP3A4\*1G* may not be considered as an independent variable in CLP resistance. It has to be noted, however, that *CYP3A4\*1G* is in the linkage disequilibrium with *CYP3A4\*1B* which is linked with *CYP3A5\*1* (*D*′ = 0.757 between *CYP3A4\*1G* and *CYP3A4\*1B*, and *D*′ \> 0.7 between *CYP3A4\*1B* and *CYP3A5\*1*) \[[@CR14], [@CR35]\]. Therefore, the presence of *\*1G* might be only a marker of yet unstudied allele of greater influence of the variability on CLP therapy.

The study has several limitations. The study group is relatively small and ethnically homogenous. Moreover, observed concentrations of CLP and its thiol metabolites H3 and H4 were very low and in a number of samples were below quantitation limit of applied method. Therefore, full pharmacokinetic profiles could not be obtained for all patients. In addition, no *\*1G/\*1G* homozygotes were observed in the studied population and the results reflect only differences between *wt/wt* and *wt/\*1G* genotypes. Presumably, a substantially larger sample size would be required to fully evaluate the gene effect.

Conclusions {#Sec14}
===========

The present study is a first to investigate the impact of *CYP3A4\*1G* on clinical pharmacokinetics of CLP and its active metabolite. It was found that there is no difference in CLP pharmacokinetics as well as pharmacodynamics in carriers of *\*1G* allele compared to wild-type homozygotes.
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